| Chief Investigator: |
Professor Claire Harrison |
| Sponsor: |
University of Birmingham |
| Funders: |
Novartis, MPN Voice and INCa (the French National Cancer Institute) |
| Disease Site: |
Haematology |
| Trial Type: |
Clinical Trial of Investigational Medicinal Products |
| Status: |
Open |
| UKCRN Study ID: (if applicable) |
39201 |
| Open to new sites? |
Yes |
| Recruitment start date: |
25th October 2019 |
| Anticipated Recruitment end date |
|
| CRCTU Trial Management Team: |
B Team |
| Trial E-mail Address: |
Mithridate@trials.bham.ac.uk |
Trial Summary
The MITHRIDATE study has been set up to investigate which treatment is most effective for patients who have high risk polycythemia vera (PV). The study will test how safe and effective a drug called ruxolitinib is when treating patients with PV compared to the current Best Available Therapy (BAT).
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Trial Protocol
Please note: Clinical trial protocols are complex technical documents, which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to the Cancer Research UK website
To view the Protocol and other trial related documents, please refer to the Investigators page.
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.